Skip to Main Content

Author Details

Samantha L Burton
2015
16
8
PMIDPaper TitleJournal TitlePublished Year
36686712Expanding the toolbox of metabolically stable lipid prodrug strategies.Front Pharmacol2023
37566734Development of a Dihydroquinoline-Pyrazoline GluN2C/2D-Selective Negative Allosteric Modulator of the -Methyl-d-aspartate Receptor.2023
37878666High throughput analysis of B cell dynamics and neutralizing antibody development during immunization with a novel clade C HIV-1 envelope.PLoS Pathog2023
37553348Intradermal but not intramuscular modified vaccinia Ankara immunizations protect against intravaginal tier2 simian-human immunodeficiency virus challenges in female macaques.Nat Commun2023
35179893Synthesis and Evaluation of Novel Tetrahydronaphthyridine CXCR4 Antagonists with Improved Drug-like Profiles.J Med Chem2022
35503780A neutralizing antibody target in early HIV-1 infection was recapitulated in rhesus macaques immunized with the transmitted/founder envelope sequence.PLoS Pathog2022
35867800A clade C HIV-1 vaccine protects against heterologous SHIV infection by modulating IgG glycosylation and T helper response in macaques.Sci Immunol2022
34459598Ï¿-Functionalized Lipid Prodrugs of HIV NtRTI Tenofovir with Enhanced Pharmacokinetic Properties.J Med Chem2021
33556148The C3/465 glycan hole cluster in BG505 HIV-1 envelope is the major neutralizing target involved in preventing mucosal SHIV infection.PLoS Pathog2021
32393800T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers.Nat Med2020
30697215VH1-69 Utilizing Antibodies Are Capable of Mediating Non-neutralizing Fc-Mediated Effector Functions Against the Transmitted/Founder gp120.Front Immunol2019
30651354Clade C HIV-1 Envelope Vaccination Regimens Differ in Their Ability To Elicit Antibodies with Moderate Neutralization Breadth against Genetically Diverse Tier 2 HIV-1 Envelope Variants.J Virol2019
27928002Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.J Virol2017
27851829Diversification in the HIV-1 Envelope Hyper-variable Domains V2, V4, and V5 and Higher Probability of Transmitted/Founder Envelope Glycosylation Favor the Development of Heterologous Neutralization Breadth.PLoS Pathog2016
26261312Breakthrough of SIV strain smE660 challenge in SIV strain mac239-vaccinated rhesus macaques despite potent autologous neutralizing antibody responses.Proc Natl Acad Sci U S A2015
26018167Characterization and Implementation of a Diverse Simian Immunodeficiency Virus SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multimodal Vaccines Expressing the SIVmac239 Envelope.J Virol2015
  • 1 - 16 of 16

Recommended Authors

Collaborators

University of Washington
Co-authored papers 15
Co-authored papers 9
Center for Family Health Research Zambia
Co-authored papers 8
Co-authored papers 6
Institute for Immunity, Stanford University School of Medicine, Stanford University
Co-authored papers 6
Co-authored papers 6
Co-authored papers 4
Co-authored papers 4
Co-authored papers 4
Co-authored papers 4
Co-authored papers 4
Co-authored papers 3
Co-authored papers 3
Co-authored papers 2
Emory University
Co-authored papers 2
Co-authored papers 2
Co-authored papers 2
Emory University
Co-authored papers 2
Co-authored papers 2
Co-authored papers 2
Co-authored papers 2
Co-authored papers 1
Co-authored papers 1
Co-authored papers 1
Co-authored papers 1
Co-authored papers 1
Co-authored papers 1
Co-authored papers 1
The University of Danang-University of Science and Technology
Co-authored papers 1
Co-authored papers 1